Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Ghofrani, D. Richards, T. Hutchinson, C. Dufton, On Behalf of the ARIES Study Group (Giessen, Germany; Harlow, Essex, United Kingdom; Westminster, CO, United States Of America). Ambrisentan therapy for PAH patients with WHO class II symptoms: one year follow-up.. Eur Respir J 2008; 32: Suppl. 52, 3178

Member's Comments

No comment yet.

Related content which might interest you: Treatment outcome and one year follow-up status of patients treated under DOTS category II Source: Annual Congress 2008 - Epidemiological and clinical aspects of tuberculosis control Year: 2008 Ambrisentan therapy for patients with PAH associated with connective tissue disease (PAH-CTD): one year follow-up Source: Annual Congress 2008 - Pulmonary arterial hypertension and other pulmonary vascular diseases Year: 2008 Bosentan delays time to clinical worsening (TTCW) and improves haemodynamics in who class II pulmonary arterial hypertension (PAH) patients: EARLY study results Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension Year: 2007 Long-term benefits of pulmonary rehabilitation in COPD patients: 2 year follow-up Source: International Congress 2017 – Novel treatments for rehabilitation of patients with chronic respiratory diseases Year: 2017 Predictive factors of clinical worsening in functional class II patients with pulmonary arterial hypertension (PAH) in the EARLY trial of bosentan Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension Year: 2008 Corticosteroids significantly improve symptom score in patients with active pulmonary sarcoidosis over a two year follow up Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders Year: 2011 Four years follow-up of exacerbations in a cohort of COPD patients: 1 year interim results (EXACO study) Source: Annual Congress 2008 - COPD - clinical and epidemiological aspects Year: 2008 One year follow-up on pulmonary function for lobectomized patients. Source: International Congress 2017 – General thoracic surgery Year: 2017 Optimizing treatment for life-threatening hemoptysis: a prospective follow-up of 101 patients over 1 year Source: Eur Respir J 2007; 30: Suppl. 51, 559s Year: 2007 Three drug regimen in SCLC-ED patients: a phase II study Source: Annual Congress 2007 - Therapy of thoracic malignancies Year: 2007 Prevalence of heart disease in patients hospitalized for an acute exacerbation of COPD: Impact on clinical outcome. A 6 month follow-up study Source: Annual Congress 2011 - COPD management Year: 2011 Decline in function in preclinical COPD patients: a 6 years follow up study. Source: International Congress 2017 – Assessing the functional status of patients with COPD Year: 2017 Long-term treatment with clarithromycin of stage II COPD patients with frequent exacerbations Source: Annual Congress 2008 - Management of COPD Year: 2008 One year follow-up of patients with idiopathic pulmonary fibrosis treated with immunosuppressive therapy Source: Annual Congress 2007 - Considerations in the management of idiopathic pulmonary fibrosis and other interstitial lung diseases Year: 2007 A ten year follow-up of former paediatric asthma patients Source: Eur Respir J 2005; 26: Suppl. 49, 233s Year: 2005 Asthma control and quality of life in asthmatic patients treated for 6 months with FDC Budesonide/Formoterol - BOREAS study: a subgroup analysis in patients with comorbidities Source: International Congress 2019 – Asthma treatment: cohorts and real-world studies Year: 2019 Responses to sitaxsentan in patients with functional class II compared to III/IV pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 548s Year: 2006 The effectiveness of plasmaferesis in patients with relapsing and progressing course of pulmonary sarcoidosis (5 years follow-up) Source: Annual Congress 2010 - Clinical issues in diffuse parenchymal lung disease Year: 2010 Patients’ adherence to treatment: How does it changes in 1 year after finishing of the participation in trial? Source: Annual Congress 2013 –New treatments and old dilemmas in the clinical management of lung diseases Year: 2013 A phase II, randomised, placebo controlled trial of 12 weeks treatment with an oral p38 inhibitor in patients with COPD on a background of ICS/LABA Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013